Al-Khudari Samer, Bendix Scott, Lindholm Jamie, Simmerman Erin, Hall Francis, Ghanem Tamer
Head & Neck Institute, Cleveland Clinic Foundation, Cleveland, OH 44106, USA.
ISRN Otolaryngol. 2013 Jul 8;2013:190364. doi: 10.1155/2013/190364. Print 2013.
Objective. To evaluate factors that influence gastrostomy tube (g-tube) use after transoral robotic surgery (TORS) for oropharyngeal (OP) cancer. Study Design/Methods. Retrospective review of TORS patients with OP cancer. G-tube presence was recorded before and after surgery at followup. Kaplan-Meier and Cox hazards model evaluated effects of early (T1 and T2) and advanced (T3, T4) disease, adjuvant therapy, and free flap reconstruction on g-tube use. Results. Sixteen patients had tonsillar cancer and 13 tongue base cancer. Of 22 patients who underwent TORS as primary therapy, 17 had T1 T2 stage and five T3 T4 stage. Seven underwent salvage therapy (four T1 T2 and three T3 T4). Nine underwent robotic-assisted inset free flap reconstruction. Seventeen received adjuvant therapy. Four groups were compared: primary early disease (PED) T1 and T2 tumors, primary early disease with adjunctive therapy (PEDAT), primary advanced disease (PAD) T3 and T4 tumors, and salvage therapy. Within the first year of treatment, 0% PED, 44% PEDAT, 40% PAD, and 57% salvage patients required a g-tube. Fourteen patients had a temporary nasoenteric tube (48.3%) postoperatively, and 10 required a g-tube (34.5%) within the first year. Four of 22 (18.2%) with TORS as primary treatment were g-tube dependent at one year and had received adjuvant therapy. Conclusion. PED can be managed without a g-tube after TORS. Similar feeding tube rates were found for PEDAT and PAD patients. Salvage patients have a high rate of g-tube need after TORS.
目的。评估影响经口机器人手术(TORS)治疗口咽(OP)癌后胃造口管(胃管)使用的因素。研究设计/方法。对接受TORS治疗的OP癌患者进行回顾性研究。在随访时记录手术前后胃管的使用情况。采用Kaplan-Meier法和Cox风险模型评估早期(T1和T2)和晚期(T3、T4)疾病、辅助治疗以及游离皮瓣重建对胃管使用的影响。结果。16例患者为扁桃体癌,13例为舌根癌。在22例接受TORS作为主要治疗的患者中,17例为T1/T2期,5例为T3/T4期。7例接受挽救性治疗(4例T1/T2期和3例T3/T4期)。9例接受机器人辅助游离皮瓣重建。17例接受辅助治疗。比较四组:原发性早期疾病(PED)T1和T2肿瘤、原发性早期疾病联合辅助治疗(PEDAT)、原发性晚期疾病(PAD)T3和T4肿瘤以及挽救性治疗。在治疗的第一年内,0%的PED患者、44%的PEDAT患者、40%的PAD患者和57%的挽救性治疗患者需要胃管。14例患者术后有临时鼻肠管(48.3%),10例在第一年内需要胃管(34.5%)。22例以TORS作为主要治疗的患者中有4例(18.2%)在1年时依赖胃管且接受了辅助治疗。结论。TORS治疗后,PED患者无需胃管即可处理。PEDAT患者和PAD患者的饲管使用率相似。挽救性治疗患者在TORS后胃管需求率较高。